Ken Griffin Roivant Sciences Ltd. Put Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	BUY	$10.17 - $12.5 $701,730 - $862,500	69,000 Added 30.26%	297,000 $3.43 Million
Q2 2024 Aug 14, 2024	SELL	$10.36 - $11.74 $318,052 - $360,418	-30,700 Reduced 11.87%	228,000 $2.41 Million
Q1 2024 May 15, 2024	BUY	$9.87 - $11.8 $398,747 - $476,720	40,400 Added 18.51%	258,700 $2.73 Million
Q4 2023 Feb 14, 2024	BUY	$8.38 - $11.58 $780,178 - $1.08 Million	93,100 Added 74.36%	218,300 $2.45 Million
Q3 2023 Nov 14, 2023	BUY	$9.76 - $13.19 $1 Million - $1.35 Million	102,500 Added 451.54%	125,200 $1.46 Million
Q2 2023 Aug 14, 2023	SELL	$7.09 - $10.08 $44,667 - $63,504	-6,300 Reduced 21.72%	22,700 $228,000
Q1 2023 May 15, 2023	BUY	$6.92 - $9.98 $74,044 - $106,786	10,700 Added 58.47%	29,000 $214,000
Q4 2022 Feb 14, 2023	SELL	$3.36 - $7.99 $4,032 - $9,588	-1,200 Reduced 6.15%	18,300 $146,000
Q3 2022 Nov 14, 2022	SELL	$0.51 - $4.84 $1,632 - $15,488	-3,200 Reduced 14.1%	19,500 $63,000

310

507M

1.26M

2.52M

Ticker ROIV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 704,382,976
Market Cap $8.45B
Description
Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.